Diagnosis and Treatment of Autoimmune Hepatitis

Gastroenterology Clinics of North America

Volumn 37, Issue 2, 2008, Pages 461-478

  Luxon, Bruce A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CORTICOSTEROID; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; KIDNEY ANTIBODY; PREDNISONE; SMOOTH MUSCLE ANTIBODY; STEROID;

ACNE; ANTIBODY TITER; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ESOPHAGUS VARICES; ETHNIC DIFFERENCE; GENETIC PREDISPOSITION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CANCER; LIVER TRANSPLANTATION; MONOTHERAPY; MOON FACE; NONHUMAN; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PORTAL HYPERTENSION; PREGNANCY; PREVALENCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SPINE INJURY; SURVIVAL; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

AUTOANTIBODIES; BIOPSY, NEEDLE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER TRANSPLANTATION;

EID: 43549092831     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2008.02.002     Document Type: Review

References (60)

1. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33 (1998) 99
2. Wiesner R.H., Demetris A.J., Belle S.H., et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (1998) 638
3. Luxon B.A. Autoimmune hepatitis. Making sense of all those antibodies. Postgrad Med 114 (2003) 79
4. Luxon B.A. Autoimmune hepatitis: diagnosis, treatment, and prognosis. Curr Gastroenterol Rep 8 (2006) 83
5. Czaja A.J., and Carpenter H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43 (2006) 532
6. Soloway R.D., Summerskill W.H., Baggenstoss A.H., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63 (1972) 820
7. Murray-Lyon I.M., Stern R.B., and Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1 (1973) 735
8. Czaja A.J. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4 (1984) 1
9. Feld J.J., Dinh H., Arenovich T., et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42 (2005) 53
10. Czaja A.J., and Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002) 479
11. Schalm S.W., Korman M.G., Summerskill W.H., et al. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 22 (1977) 973
12. Czaja A.J. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 57 (1999) 49
13. Alvarez F., Berg P.A., Bianchi F.B., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929
14. Kogan J., Safadi R., Ashur Y., et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 35 (2002) 75
15. Davis G.L., Czaja A.J., and Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 87 (1984) 1222
16. Verma S., Gunuwan B., Mendler M., et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 99 (2004) 1510
17. Roberts S.K., Therneau T.M., and Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110 (1996) 848
18. Czaja A.J. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6 (2002) 799
19. Verma S., and Redeker A. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome?. Hepatology 42 (2005) 1237 [author reply 1237]
20. Heathcote J. Treatment strategies for autoimmune hepatitis. Am J Gastroenterol 101 (2006) S630
21. Dufour J.F., DeLellis R., and Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (1997) 981
22. Czaja A.J., and Carpenter H.A. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39 (2004) 1631
23. Johnson P.J., and McFarlane I.G. Meeting report: international autoimmune hepatitis group. Hepatology 18 (1993) 998
24. Goldberg A.C., Bittencourt P.L., Oliveira L.C., et al. Autoimmune hepatitis in Brazil: an overview. Scand J Immunol 66 (2007) 208
25. Ben-Ari Z., and Czaja A.J. Autoimmune hepatitis and its variant syndromes. Gut 49 (2001) 589
26. Czaja A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28 (1998) 360
27. Czaja A.J., and Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 34 (2001) 659
28. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 31 (2000) 1231
29. Czaja A.J., and Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105 (1993) 1824
30. Czaja A.J., and Manns M.P. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 90 (1995) 1206
31. Meyer O., Abuaf N., Cyna L., et al. Anti-mitochondrial type 5 antibodies and anti-cardiolipin antibodies in systemic lupus erythematosus and auto-immune diseases. Clin Exp Immunol 69 (1987) 485
32. Czaja A.J., Cassani F., Cataleta M., et al. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 42 (1997) 1688
33. Czaja A.J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 30 (1999) 394
34. Kogure T., Ueno Y., Fukushima K., et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 13 (2007) 4394
35. Manns M., Zanger U., Gerken G., et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 12 (1990) 127
36. Manns M.P., Griffin K.J., Sullivan K.F., et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88 (1991) 1370
37. Czaja A.J., Manns M.P., and Homburger H.A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103 (1992) 1290
38. Czaja A.J., and Freese D.K. American Association for the Study of Liver Disease: diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002) 479
39. McFarlane I.G., Hegarty J.E., McSorley C.G., et al. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 2 (1984) 954
40. Treichel U., Gerken G., Rossol S., et al. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 19 (1993) 55
41. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355 (2000) 1510
42. Baggenstoss A.H., Soloway R.D., Summerskill W.H., et al. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3 (1972) 183
43. Uribe M., Go V.L., and Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 6 (1984) 331
44. Summerskill W.H., Korman M.G., Ammon H.V., et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16 (1975) 876
45. Czaja A.J., Davis G.L., Ludwig J., et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4 (1984) 622
46. Czaja A.J., Wolf A.M., and Baggenstoss A.H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80 (1981) 687
47. Hegarty J.E., Nouri Aria K.T., Portmann B., et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3 (1983) 685
48. Montano-Loza A.J., Carpenter H.A., and Czaja A.J. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 102 (2007) 1005
49. Al-Chalabi T., and Heneghan M.A. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?. Am J Gastroenterol 102 (2007) 1013
50. Heneghan M.A., Norris S.M., O'Grady J.G., et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 48 (2001) 97
51. Buchel E., Van Steenbergen W., Nevens F., et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 97 (2002) 3160
52. Schramm C., Herkel J., Beuers U., et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 101 (2006) 556
53. Steven M.M., Buckley J.D., and Mackay I.R. Pregnancy in chronic active hepatitis. Q J Med 48 (1979) 519
54. Prados E., Cuervas-Mons V., de la Mata M., et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 66 (1998) 1645
55. Wright H.L., Bou-Abboud C.F., Hassanein T., et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 53 (1992) 136
56. Duclos-Vallee J.C., Sebagh M., Rifai K., et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 52 (2003) 893
57. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 32 (2000) 185
58. Gonzalez-Koch A., Czaja A.J., Carpenter H.A., et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 7 (2001) 302
59. Milkiewicz P., Hubscher S.G., Skiba G., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68 (1999) 253
60. Gautam M., Cheruvattath R., and Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 12 (2006) 1813